All News
APEX Phase 3b trial: #guselkumab (Q4W or Q8W) reduces joint damage in #PsA
✅ ACR20: 67–68% vs 47% (PBO)
✅ ↓radiographic progression (vdH-S: 0.55/0.54 vs 1.35)
No new safety signals identified.
@RheumNow #EULAR2025 #LB0010 https://t.co/LLN1TXvOC3
Mrinalini Dey DrMiniDey ( View Tweet)
#GameChanger
Subset analysis of #CTD Pts with
Progressive pulmonary fibrosis
#PPF
Ok background #nintedanib 1/3
❎lung IS
2 doses #PDE4Bi #nerandomilast vs #PBO
each dose ⬇️worsening #FVC vs PBO
⬇️lung events - hospital
⬇️death
GI A/E
#EULAR2025 Latebreakers I @RheumNow https://t.co/PWKEnpyyMN
Links:
Janet Pope Janetbirdope ( View Tweet)
Genicular artery embolisation is like so many interventions in MSK medicine:
early promise with smaller RCT & observational data, but the later, more robust data doesn’t show the same benefit.
If you do meta-analyses of all these data, you mix good with bad
#EULAR2025 @RheumNow https://t.co/K1tN9KX8rq
David Liew drdavidliew ( View Tweet)
Management and prognosis of RP by @Lupusreference
1. Pts with mild disease respond to GCs
2. NSAIDs/colchicine good alternatives
3. Most common biologics used: TNFi and IL6i
4. Consider CYP in life threatening dz/ICU pts
5. Dynamic CT assess tracheal collapse.
6. PET-CT can ≠ https://t.co/PNUecMZvkT
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Results from open label
extension of BE-OPTIMAL:
-Bimekizumab in bDMARD naïve pts showed sustained efficacy after 1y until 3y.
-No significant major tolerability issues or major SE.
abstract #POS1294
#EULAR2025
@RheumNow https://t.co/VAEiciCR1z
Adela Castro AdelaCastro222 ( View Tweet)
ICI-PMR irAEs are sometimes underestimated compared to inflamm arthritis, but why?
ICI-IA and ICI-PMR look different, but at @HSpecialSurgery, steroid needs and disease impact for both are basically the same. Let’s not devalue either
@lovetolearn27 #EULAR2025 POS1200 @RheumNow https://t.co/NVq2tpjvdu
Links:
David Liew drdavidliew ( View Tweet)
#EULAR2025 Abstr#POS0301 Real World Multicentre study in Italy reported higher proportion of CRR at 6-mth & Lower GC in people with #lupus nephritis (~96% Class III, IV or Mixed with V) treated with Belimumab+SOC vs matched cohort on SOC. Predicted by early BEL use @RheumNow https://t.co/D6e2qo9NRL
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
✅Exciting results from POETYK PsA-1: -Deucravacitinib (TYK2i) in PsA
-ACR 20 was achieved in significantly more patients treated with deucravacitinib vs placebo at W16 (54.2% vs 34.1%; P < 0.0001), with similar results for ACR 50 and ACR 70
-Also met 2dary endpoints.
-Post hoc https://t.co/S4DhovMCma
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Hidradenitis suppurativa is newer to us in rheumatology, but it seems like inflamm arthritis is a problem - at least to a similar extent as in psoriasis.
Time for us to look for it & to see what therapies like IL-17 inhibitors do for this arthritis
#EULAR2025 POS1237 @RheumNow https://t.co/b5EQdDEAhq
David Liew drdavidliew ( View Tweet)
Social disparities in rheumatology @RheumNow #EULAR2025
~70% of outcomes are determined by Social determinants of health
Modifiable factors ? Maybe? https://t.co/UfC2nQ5Azy
Bella Mehta bella_mehta ( View Tweet)
@RheumNow Achieving health equity is the goal
1.4% of GDP is lost in health inequity in EU https://t.co/50M4SfuxvX
Bella Mehta bella_mehta ( View Tweet)
How much of the health outcomes are related to social determinants?
🔺️Up to 75%!
Disaster Medicine Session
Social disparities and impact on outcomes
Dr Kate Webb
#EULAR2025
@RheumNow https://t.co/0Ahbf79Nbx
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2025 Abstr#LB0007 Two’s Company, Three’s a Crowd! In 5 #SLE pts treated with CC312, a novel CD19/CD3/CD28 tri-specific ab in dose escalation showed rapid & B-cell depletion & all achieved SRI-4. No =>G2 CRS or ICANS. USP: off-the-shelf & overcome T-cell exhaustion @RheumNow https://t.co/6DZRj09JEQ
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Low disease activity more difficult to achieve in vulnerable populations.
All rheumatic diseases - #RA #PsA #AS
initiating DMARDs takes longer in these population
#EULAR2025 @RheumNow https://t.co/voIivshKRt
Bella Mehta bella_mehta ( View Tweet)
What do we know about disparities in #SLE
- worse in women
- worse in non white populations
- have lower quality of care in vulnerable populations
- have worse outcomes in vulnerable populations
#EULAR2025 @rheumnow
Diagnosis itself is difficult in communities with poor access https://t.co/pcUaJ0eK65
Bella Mehta bella_mehta ( View Tweet)
#Lupus is one of the biggest social discriminators
🔺️Higher prevalence in Women
🔺️Higher prevalence in Non-Whites
🔺️More catastrophic manifestations in low socioeconomic groups
Disaster Medicine Session
Social disparities and impact on outcomes
#EULAR2025
@RheumNow https://t.co/mewR9NzXHt
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Dual pandemic in Africa.
Increasing lifestyle diseases and obesity, along with infections and malnutrition.
These may be reflected in rheumatic diseases too (if they could be studied in detail)
#EULAR2025 @RheumNow https://t.co/6ulMRxX8az
Links:
Bella Mehta bella_mehta ( View Tweet)
Targets for OA pain pharmacotherapies
some by the wayside:
- NGF
- TrkA
but some very much in play and exciting:
- neurotrophin-3
- TRPV1
- Nav1.7, 1.8
Fiona Watt #EULAR2025 @RheumNow https://t.co/DXDKNnVRRo
David Liew drdavidliew ( View Tweet)
In the APEX Phase 3b RCT (N=1020), guselkumab (IL-23p19 inhibitor) significantly reduced radiographic progression (ΔvdH-S 0.55 & 0.54 vs 1.35 PBO; p≤0.002) and improved ACR20 (67–68% vs 47%) at W24 in biologic-naïve PsA. Safety consistent with prior data. Abstract LB0010 https://t.co/mFDsBsCg6m
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Migrant health literacy challenges - Individual interviews with participants with rheumatic diseases (interpreters used)
multiple aspects -
Individual, Providers and system level
Navigating health care systems
#EULAR2025 @RheumNow https://t.co/cWQ6jP8RZe
Bella Mehta bella_mehta ( View Tweet)
